Your browser doesn't support javascript.
loading
Remission of Rheumatoid Arthritis and Primary Biliary Cholangitis After Treatment With Tocilizumab / Remisión de artritis reumatoide y colangitis biliar primaria tras tratamiento con tocilizumab
Azevedo, Soraia; Sousa-Neves, Joana; Ramos Rodrigues, Joana; Peixoto, Daniela; Tavares-Costa, José; Teixeira, Filipa.
Affiliation
  • Azevedo, Soraia; Unidade Local de Saúde do Alto Minho. Rheumatology Department. Ponte de Lima. Portugal
  • Sousa-Neves, Joana; Hospital de Braga. Rheumatology Department. Portugal
  • Ramos Rodrigues, Joana; Unidade Local de Saúde do Alto Minho. Rheumatology Department. Ponte de Lima. Portugal
  • Peixoto, Daniela; Unidade Local de Saúde do Alto Minho. Rheumatology Department. Ponte de Lima. Portugal
  • Tavares-Costa, José; Unidade Local de Saúde do Alto Minho. Rheumatology Department. Ponte de Lima. Portugal
  • Teixeira, Filipa; Unidade Local de Saúde do Alto Minho. Rheumatology Department. Ponte de Lima. Portugal
Reumatol. clín. (Barc.) ; 17(6): 364-365, Jun-Jul. 2021.
Article in En | IBECS | ID: ibc-213323
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Rheumatoid arthritis (RA) is characterized by synovitis of multiple joints which if untreated progresses to joint destruction. Primary biliary cholangitis (PBC) is an autoimmune and progressive disease of the liver of unknown origin. About 1.8–5.6% of individuals with PBC have RA and patients with RA are at higher risk of developing PBC compared to the general population. We report a case of a 76-year-old man, with a history of PBC, and a recent RA diagnosis, in which tocilizumab therapy was effective in the control of RA and PBC, and a literature review was performed. This case, along with only one case published in literature in which tocilizumab was used in the treatment of RA and PBC, suggests that tocilizumab may be effective and safe in the treatment of RA in patients with PBC. Inhibition of IL-6 may also be effective in PBC treatment.(AU)
RESUMEN
La artritis reumatoide (AR) se caracteriza por sinovitis de múltiples articulaciones que, de no tratarse, deriva en destrucción articular. La colangitis biliar primaria (CBP) es una enfermedad hepática autoinmune y progresiva de origen desconocido. Cerca del 1,8-5,6% de los individuos con CBP padecen AR, y los pacientes con AR tienen mayor riesgo de desarrollar CBP, en comparación con la población general. Reportamos el caso de un varón de 76 años con historia de CBP y diagnóstico reciente de AR, en el que la terapia con tocilizumab fue efectiva para el control de ambas situaciones y realizamos una revisión de la literatura sobre el caso. Este caso junto con otro publicado en la literatura, en el que se utilizó tocilizumab para tratar CBP y AR, sugieren que este fármaco puede ser efectivo y seguro para el tratamiento de AR en pacientes con CBP. La inhibición de IL-6 puede resultar también eficaz en el tratamiento de la CBP.(AU)
Subject(s)
Key words

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Physical Examination / Referral and Consultation / Inpatients / Liver Cirrhosis, Biliary / Antibodies, Monoclonal Limits: Aged / Humans / Male Language: En Journal: Reumatol. clín. (Barc.) Year: 2021 Document type: Article

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Physical Examination / Referral and Consultation / Inpatients / Liver Cirrhosis, Biliary / Antibodies, Monoclonal Limits: Aged / Humans / Male Language: En Journal: Reumatol. clín. (Barc.) Year: 2021 Document type: Article